Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Profit After Tax (2016 - 2025)

ImmunityBio (IBRX) has disclosed Profit After Tax for 12 consecutive years, with -$61.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax fell 4.6% to -$61.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$351.4 million, a 15.04% increase, with the full-year FY2025 number at -$351.4 million, up 15.03% from a year prior.
  • Profit After Tax was -$61.9 million for Q4 2025 at ImmunityBio, up from -$67.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$59.2 million in Q4 2024 to a low of -$233.4 million in Q4 2023.
  • A 5-year average of -$105.8 million and a median of -$95.2 million in 2022 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: crashed 306.08% in 2021, then skyrocketed 74.65% in 2024.
  • ImmunityBio's Profit After Tax stood at -$91.6 million in 2021, then decreased by 18.2% to -$108.2 million in 2022, then crashed by 115.67% to -$233.4 million in 2023, then surged by 74.65% to -$59.2 million in 2024, then fell by 4.6% to -$61.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Profit After Tax are -$61.9 million (Q4 2025), -$67.3 million (Q3 2025), and -$92.6 million (Q2 2025).